Académique Documents
Professionnel Documents
Culture Documents
Primeboost vaccination
Repeated immunizations that
are administered when a single
application of a vaccine is
insufficient, using the same
vaccine preparation
(homologous primeboost)
or using different vaccine
preparations (heterologous
primeboost) to sequentially
stimulate a stronger immune
response. Prior exposure to
one vaccine strain can elicit
antibody and Tcell responses
to shared epitopes following
exposure to a second vaccine
strain, increasing the efficacy
of heterologous primeboost
regimens.
www.nature.com/reviews/immunol
2009 Macmillan Publishers Limited. All rights reserved
REVIEWS
a
Antibody secretion
iNKT cell
B cell
CD1d
Lipid
TCR
CD40
CD40L
Microbial-derived
lipid
CD40
CD40L
CD1d
Lysosome
TCR
CD1d
TCR
DC
DC
iNKT cell
IL-4?
Microorganism
CD40L
CD27 CD70
CD40
TCR
OX40
OX40L
CD1d
MDSC
NOS2 production
Arginase 1 production
IFN
IL-12
NK cell
iNKT cell
CD8+
T cell
CD4+
T cell
IL-12, IL-18
and type I IFN
TCR
Endogenous
lipid
CD1d
TLR
Lytic function
IFN production
Proliferation
Lytic function
Cytokine production
DC
Lysosome
Figure 1 | Natural killer T cells interact with and modulate the function of many different cell types. a | Invariant
natural killer T (iNKT) cells directly and indirectly modulate the function of many other cell types, such as NK cells and
T cells. These interactions are bidirectional, as iNKT cells receive signals from antigen-presenting
cellsReviews
(APCs) and
vice
Nature
| Immunology
versa. Signals can be received through cell-surface receptors, such as T-cell receptors (TCRs) recognizing glycolipidCD1d
complexes, co-stimulatory receptors, such as CD40, CD27 and OX40 recognizing their ligands CD40L, CD70 and OX40L,
respectively, as well as through soluble mediators, such as cytokines. Activated iNKT cells inhibit the function of
myeloid-derived suppressor cells (MDSCs), which suppress immune responses with nitric oxide synthase 2 (NOS2) and
arginase 1. b | APCs infected with microorganisms can process microbial glycolipids and present them by CD1d molecules,
which results in iNKT-cell activation. c | Signalling through Toll-like receptors (TLRs) leads to the presentation of
endogenous glycolipids by CD1d molecules that, together with the secretion of interleukin-12 (IL-12), activate iNKT cells.
TLR-induced release of soluble mediators, such as IL-12, IL-18 and type I interferons (IFNs), can also activate iNKT cells in a
CD1d-independent manner. DC, dendritic cell.
REVIEWS
Box 1 | Phenotype of invariant natural killer T cells
Natural killer T (NKT) cells are a heterogeneous population of cells that express a Tcell receptor (TCR) and are restricted
by the CD1d molecule98. Most NKT cells (known as invariant NKT cells; iNKT cells) express an invariant TCR chain
(V14J18 in mice and the homologous V24J18 in humans) that is paired with a semiinvariant TCR chain (V2,
V7 or V8.2 in mice and V11 in humans). iNKT cells can be identified by staining with multimeric complexes of CD1d
molecules loaded with the lipid galactosylceramide (GalCer)99101. In mice iNKT cells are either CD4+ or double
negative (DN) for coreceptor expression, whereas in humans a CD8+ subset of iNKT cells also exists. It has been shown
that these subsets have slightly different functional properties: human DN and CD8+ iNKT cells are highly cytolytic and
produce T helper 1 (TH1)type cytokines, whereas CD4+ iNKT cells produce both TH1 and TH2type cytokines102,103 and
differentially regulate dendriticcell activity104. In addition, the antitumour activity of iNKT cells has been shown to apply
mainly to the liver DN subset in two mouse models105.
Although iNKTcell maturation in the periphery has previously been associated with the acquisition of NK1.1 expression,
a population of mature NK1.1 iNKT cells has recently been reported106. Furthermore, a CD4NK1.1 subset that produces
interleukin17 (IL17) and constitutively expresses IL23 and retinoicacidreceptorrelated orphan receptort (RORt) has
been identified58,107. IL17 secretion may contribute to their pathogenic role in several diseases108,109.
iNKT cells are found in abundance in the thymus, spleen, liver and bone marrow, which may be explained by their
expression of a chemokine receptor profile that is similar to that of TH1 cells which home to inflamed tissues. Few
iNKT cells express lymphnode homing receptors110113.
www.nature.com/reviews/immunol
2009 Macmillan Publishers Limited. All rights reserved
REVIEWS
a Natural ligands
O
HO
HN
OH
O
HO
HO
OH
OH
OH
O
OH
O
OH
O
HO
O
O
OH
HO
OH
HO
OH
OH
HO
HO
O
O
O
OH
HO
O
O
HO
HO
HO
Phosphatidylinositol tetramannoside
(M. leprae)
OH
O
HO
HO
HN
OH
HO
HO
HO
OH
HO
OH
HO
HO O
O
Isoglobotrihexosylceramide (endogenous)
O HO
OH
O
OH
O
b Synthetic ligands
O
HN
OH
O
OH
HN
OH
HO
OH
HO
-Galactosylceramide (synthetic or
marine sponge)
O
HN
OH
O
O
OH
HO
OH
HO
C20:2
OH
Threitolceramide
HO
OH
OH
HO
O
HN
OH
O
O
OH
HO
OCH9
OH
-C-galactosylceramide
O
OH
OH
O
OH
HO
OH
H2
C
HN
OH
OH
HO
HO
REVIEWS
Box 2 | Invariant-natural-killer-T-cell endogenous ligands
The nature of the antigen (or antigens) mediating invariant natural killer T (iNKT)cell selection in the thymus is still
uncertain. Evidence from a glucosylceramidesynthasedeficient cell line that cannot stimulate V14+ iNKT cells
suggested that the natural ligand is a glycosphingolipid114. The endogenous glycosphingolipid isoglobotrihexosyl
ceramide (iGb3) (FIG. 2), an agonist for human and mouse iNKT cells115, was initially considered to be the only natural
selecting ligand for these cells, as mice deficient in the lysosomal enzyme hexosaminidase, which generates iGb3 from
iGb4, had impaired iNKTcell development115.
However, subsequent work revealed that mice lacking other lysosomal enzymes that are involved in glycosphingolipid
catabolism and in cholesterol transport have severe defects in iNKTcell development (reviewed in ReF.116). It is probable
that altered lipid trafficking and lysosomal processing, which are common to all these mutant mice, account for the
defect in iNKTcell development. Indeed, analysis of iGb3synthasedeficient mice did not reveal any anomaly in the number
or function of iNKT cells117. iGb3 was not detected by a sensitive highperformance liquid chromatography in the thymi
of these mice or in their dendritic cells (DCs)118, despite an earlier report that it may mediate the recognition of
lipopolysaccharidematured DCs8. Finally, iGb3 was not detected in any human tissue118, which is consistent with the
observation that humans lack a functional iGb3 synthase owing to several mutations in the gene that encodes it119.
More recently, however, the presence of iGb4 has been detected in the human thymus using mass spectrometry120.
Therefore, the biochemical identification of iGb3 remains an open question.
The identity of the lipid (or lipids) that mediates iNKTcell activation in the periphery is also under investigation. It has
recently been shown that Tolllike receptor (TLR)mediated activation of DCs enhances the expression of transcripts of
several glycosyltransferases that are involved in the biosynthesis of glycosphingolipids15,16, and mouse TLRstimulated
DCs produce a charged linked glycosphingolipid that can activate iNKT cells together with type I interferon15. Other
endogenous antigens that have been reported to activate subsets of mouse iNKT cells are phospholipids121 and the
gangliosides GD3 and GM3, which are often overexpressed in melanomas and other tumours of neuroectodermal origin122.
Cytokine storm
A strong systemic immune
response that results in the
release of high levels of
inflammatory mediators (such
as cytokines, oxygen free
radicals and coagulation
factors). Both proinflammatory
cytokines (such as
tumournecrosis factor,
interleukin1 (IL1) and IL6)
and antiinflammatory
cytokines (such as IL10 and
IL1 receptor antagonist) are
increased in the serum of
patients experiencing a
cytokine storm.
www.nature.com/reviews/immunol
2009 Macmillan Publishers Limited. All rights reserved
REVIEWS
Box 3 | Non-invariant natural killer T cells
A second population of natural killer T (NKT) cells exists (known as type II NKT cells),
which is CD1d restricted but does not express an invariant Tcell receptor (TCR) and
lacks reactivity to galactosylceramide. Type II NKT cells were first described in 1995
(ReF. 123), but their characterization has been limited because of the lack of specific
markers and agonistic reagents. More recently, a fraction of type II NKT cells has been
shown to be reactive to the selfglycolipid sulphatide and has been detected by the
ability of these cells to bind sulphatideloaded CD1d tetramers124. Type II NKT cells
have an important immuneregulatory role in infection, autoimmune disease and
tumour immunosurveillance (recently reviewed in ReF.125). In contrast to invariant
iNKT cells, type II NKT cells suppress antitumour immunity, thereby promoting the
activation of myeloidderived suppressor cells through the production of interleukin13.
T-cell anergy
A state of Tcell
unresponsiveness to
stimulation with antigen.
Tcell anergy can be induced
by stimulation with a large
amount of specific antigen
in the absence of the
engagement of costimulatory
molecules.
REVIEWS
b
a
C
TCR
iNKT-cell TCR
V
-GalCer
Peptide
CD1d
HLA-A2
2m
2m
c
Lipid chains
F70
CDR
loops
F84
Peptide
131
C12
A channel
V98
F114
V116
F channel
e -GalCer
f Threitolceramide
F29
CDR3
R95
HLA-A2
CDR1
G96
F29
CDR2
S30
S30 F51
G96
3'-OH
4'-OH
2'-OH
R95
W153
F51
3'-OH
4'-OH
2'-OH
W153
www.nature.com/reviews/immunol
2009 Macmillan Publishers Limited. All rights reserved
REVIEWS
Initial experiments carried out to establish the con
tribution of the glycosidic portion of GalCer to iNKT
cell activation showed that substitution of galactose with
glucose reduced activation and that mannosylceramide
or GalCer were not recognized by iNKT cells 18.
Although more recent results have shown that linked
glycosphingolipids, such as some forms of anomeric
GalCer, can stimulate iNKT cells88,89, it remains unclear
whether these results were due to the potential contami
nation by linked glycosphingolipid that can occur
during the synthesis of these compounds. Additional
studies correlating structure with function indicated
that the glycolipidCD1dTCR interaction tolerates a
small molecule at the carbon 6 position on the sugar of
GalCer, but that iNKTcell activation is inhibited by
other substitution patterns (reviewed in ReF. 20).
until recently, all the known iNKTcell agonists
contained a glycosidic group in the polar head. we have
now shown that iNKT cells can also recognize com
pounds that lack a sugar head and have nonglycosidic
linkages between the hydrophilic head and the ceramide
moiety 25 (FIGs 2,3f). These compounds comprise a new
class of iNKTcell agonists, and this broadens the range
of compounds that can be recognized by these cells. Of
particular interest is threitolceramide, which is similar to
GalCer in that it stably binds CD1d molecules owing to
the optimal length of its lipid chains and it is likely to form
the three hydrogen bonds with CD1d molecules because
of the presence of 4OH, 3OH and 2OH residues in the
head group25 (FIG. 3f). we have shown that threitolceramide
can induce optimal DC maturation and antigenspecific
B and Tcell priming, but does not cause extensive iNKT
celldependent lysis of DCs, as is observed with GalCer.
This is probably because of its weaker binding affinity to
the iNKTcell TCR25. Furthermore, iNKT cells that have
been activated by threitolceramide recover more quickly
from anergy than those stimulated by GalCer 25.
REVIEWS
Immunization with in vitro expanded iNKT cells.
Similarly to the clinical trials that have been carried
out using in vitro expanded peptidespecific T cells for
immunotherapy (reviewed in ReF. 95), a clinical trial
was performed using adoptively transferred iNKT cells.
Patients with nonsmallcell lung cancer received two
intravenous injections of up to 5 x 107 cells per m2 in vitro
activated (with GalCer and IL2) iNKT cells96. There
were no severe adverse events in any of the patients,
and in some cases increased frequencies of iNKT cells
were detected in blood samples postimmunization.
Administration of activated iNKT cells also induced IFN
production in vivo, mainly from NK cells. Nevertheless,
none of the patients had any notable positive clinical
response to this immunotherapy.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
www.nature.com/reviews/immunol
2009 Macmillan Publishers Limited. All rights reserved
REVIEWS
31. Renukaradhya, G. J. et al. Type I NKT cells protect
(and type II NKT cells suppress) the hosts innate
antitumor immune response to a B-cell lymphoma.
Blood 111, 56375645 (2008).
32. Spada, F. M., Koezuka, Y. & Porcelli, S. A. CD1drestricted recognition of synthetic glycolipid antigens
by human natural killer T cells. J. Exp. Med. 188,
15291534 (1998).
33. Vincent, M. S. et al. CD1-dependent dendritic cell
instruction. Nature Immunol. 3, 11631168 (2002).
34. Fujii, S., Liu, K., Smith, C., Bonito, A. J. & Steinman,
R. M. The linkage of innate to adaptive immunity via
maturing dendritic cells in vivo requires CD40 ligation
in addition to antigen presentation and CD80/86
costimulation. J. Exp. Med. 199, 16071618 (2004).
35. Hermans, I. F. et al. NKT cells enhance CD4+ and
CD8+ T cell responses to soluble antigen in vivo
through direct interaction with dendritic cells.
J. Immunol. 171, 51405147 (2003).
36. Gonzalez-Aseguinolaza, G. et al. Natural killer T cell
ligand -galactosylceramide enhances protective
immunity induced by malaria vaccines. J. Exp. Med.
195, 617624 (2002).
37. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L. &
Steinman, R. M. Activation of natural killer T cells
by -galactosylceramide rapidly induces the full
maturation of dendritic cells in vivo and thereby acts
as an adjuvant for combined CD4 and CD8 T cell
immunity to a coadministered protein. J. Exp. Med.
198, 267279 (2003).
References 3537 show that co-injection of
-GalCer with antigenic proteins increases
antigen-specific B- and T-cell responses.
38. Silk, J. D. et al. Utilizing the adjuvant properties of
CD1d-dependent NK T cells in T cell-mediated
immunotherapy. J. Clin. Invest. 114, 18001811
(2004).
39. Stober, D., Jomantaite, I., Schirmbeck, R. & Reimann, J.
NKT cells provide help for dendritic cell-dependent
priming of MHC class I-restricted CD8+ T cells in vivo.
J. Immunol. 170, 25402548 (2003).
40. Taraban, V. Y. et al. Invariant NKT cells promote
CD8+ cytotoxic T cell responses by inducing CD70
expression on dendritic cells. J. Immunol. 180,
46154620 (2008).
41. Zaini, J. et al. OX40 ligand expressed by DCs
costimulates NKT and CD4+ Th cell antitumor
immunity in mice. J. Clin. Invest. 117, 33303338
(2007).
42. Hermans, I. F. et al. Dendritic cell function can be
modulated through cooperative actions of TLR ligands
and invariant NKT cells. J. Immunol. 178,
27212729 (2007).
43. Reis e Sousa, C. Dendritic cells in a mature age.
Nature Rev. Immunol. 6, 476483 (2006).
44. Galli, G. et al. CD1d-restricted help to B cells
by human invariant natural killer T lymphocytes.
J. Exp. Med. 197, 10511057 (2003).
45. Galli, G. et al. Invariant NKT cells sustain specific
B cell responses and memory. Proc. Natl Acad. Sci.
USA 104, 39843989 (2007).
46. Barral, P. et al. B cell receptor-mediated uptake
of CD1d-restricted antigen augments antibody
responses by recruiting invariant NKT cell help
in vivo. Proc. Natl Acad. Sci. USA 105, 83458350
(2008).
47. Leadbetter, E. A. et al. NK T cells provide lipid
antigen-specific cognate help for B cells. Proc. Natl
Acad. Sci. USA 105, 83398344 (2008).
References 4547 describe the ability of
iNKT cells to directly provide help to B cells.
References 46 and 47 describe two new protocols
to promote antibody responses in vivo by recruiting
iNKT cells.
48. Fujii, S., Shimizu, K., Kronenberg, M. & Steinman, R. M.
Prolonged IFN--producing NKT response induced
with -galactosylceramide-loaded DCs. Nature
Immunol. 3, 867874 (2002).
49. Schmieg, J., Yang, G., Franck, R. W., Van Rooijen, N. &
Tsuji, M. Glycolipid presentation to natural killer
T cells differs in an organ-dependent fashion.
Proc. Natl Acad. Sci. USA 102, 11271132 (2005).
50. Ko, S. Y. et al. -galactosylceramide can act as a nasal
vaccine adjuvant inducing protective immune
responses against viral infection and tumor.
J. Immunol. 175, 33093317 (2005).
51. Kamijuku, H. et al. Mechanism of NKT cell
activation by intranasal coadministration of
-galactosylceramide, which can induce crossprotection against influenza viruses. Mucosal
Immunol. 1, 208218 (2008).
52. Chung, Y., Chang, W. S., Kim, S. & Kang, C. Y. NKT cell
ligand -galactosylceramide blocks the induction of
oral tolerance by triggering dendritic cell maturation.
Eur. J. Immunol. 34, 24712479 (2004).
53. Huang, Y. et al. Enhancement of HIV DNA vaccine
immunogenicity by the NKT cell ligand,
-galactosylceramide. Vaccine 26, 18071816 (2008).
54. Gabrilovich, D. I. et al. The terminology issue for
myeloid-derived suppressor cells. Cancer Res. 67,
425 (2007).
55. Crowe, N. Y. et al. Glycolipid antigen drives rapid
expansion and sustained cytokine production by
NK T cells. J. Immunol. 171, 40204027 (2003).
56. Wilson, M. T. et al. The response of natural killer
T cells to glycolipid antigens is characterized by
surface receptor down-modulation and expansion.
Proc. Natl Acad. Sci. USA 100, 1091310918 (2003).
57. Harada, M. et al. Down-regulation of the invariant
V14 antigen receptor in NKT cells upon activation.
Int. Immunol. 16, 241247 (2004).
58. Coquet, J. M. et al. Diverse cytokine production
by NKT cell subsets and identification of an
IL-17-producing CD4NK1.1NKT cell population.
Proc. Natl Acad. Sci. USA 105, 1128711292
(2008).
59. Miyamoto, K., Miyake, S. & Yamamura, T. A synthetic
glycolipid prevents autoimmune encephalomyelitis by
inducing TH2 bias of natural killer T cells. Nature 413,
531534 (2001).
60. Chang, Y. J. et al. Potent immune-modulating and
anticancer effects of NKT cell stimulatory glycolipids.
Proc. Natl Acad. Sci. USA 104, 1029910304
(2007).
61. Schmieg, J., Yang, G., Franck, R. W. & Tsuji, M.
Superior protection against malaria and melanoma
metastases by a C-glycoside analogue of the natural
killer T cell ligand -galactosylceramide. J. Exp. Med.
198, 16311641 (2003).
62. Bezbradica, J. S. et al. Distinct roles of dendritic cells
and B cells in Va14Ja18 natural T cell activation
in vivo. J. Immunol. 174, 46964705 (2005).
63. Yu, K. O. et al. Modulation of CD1d-restricted
NKT cell responses by using N-acyl variants of
-galactosylceramides. Proc. Natl Acad. Sci. USA 102,
33833388 (2005).
64. Gadola, S. D. et al. Structure and binding kinetics of
three different human CD1d--galactosylceramidespecific T cell receptors. J. Exp. Med. 203, 699710
(2006).
65. Sidobre, S. et al. The T cell antigen receptor
expressed by V14i NKT cells has a unique mode of
glycosphingolipid antigen recognition. Proc. Natl
Acad. Sci. USA 101, 1225412259 (2004).
66. Chiba, A., Dascher, C. C., Besra, G. S. & Brenner, M. B.
Rapid NKT cell responses are self-terminating during
the course of microbial infection. J. Immunol. 181,
22922302 (2008).
67. Schwartz, R. H. T cell anergy. Annu. Rev. Immunol. 21,
305334 (2003).
68. Ota, T. et al. IFN--mediated negative feedback
regulation of NKT-cell function by CD94/NKG2.
Blood 106, 184192 (2005).
69. Chang, D. H. et al. Sustained expansion of NKT cells
and antigen-specific T cells after injection of
-galactosyl-ceramide loaded mature dendritic cells in
cancer patients. J. Exp. Med. 201, 15031517 (2005).
70. Koch, M. et al. The crystal structure of human CD1d
with and without -galactosylceramide. Nature
Immunol. 6, 819826 (2005).
71. Zajonc, D. M. et al. Structure and function of a potent
agonist for the semi-invariant natural killer T cell
receptor. Nature Immunol. 6, 810818 (2005).
72. Borg, N. A. et al. CD1d-lipid-antigen recognition by
the semi-invariant NKT T-cell receptor. Nature 448,
4449 (2007).
73. Godfrey, D. I., Rossjohn, J. & McCluskey, J. The
fidelity, occasional promiscuity, and versatility of
T cell receptor recognition. Immunity 28, 304314
(2008).
74. Wu, D. et al. Design of natural killer T cell activators:
structure and function of a microbial glycosphingolipid
bound to mouse CD1d. Proc. Natl Acad. Sci. USA
103, 39723977 (2006).
75. Zajonc, D. M., Savage, P. B., Bendelac, A., Wilson, I. A.
& Teyton, L. Crystal structures of mouse CD1diGb3
complex and its cognate V14 T cell receptor suggest
a model for dual recognition of foreign and self
glycolipids. J. Mol. Biol. 377, 11041116 (2008).
76. Scott-Browne, J. P. et al. Germline encoded
recognition of diverse glycolipids by NKT cells.
Nature Immunol. 8, 11051113 (2007).
REVIEWS
99. Benlagha, K., Weiss, A., Beavis, A., Teyton, L. &
Bendelac, A. In vivo identification of glycolipid antigenspecific T cells using fluorescent CD1d tetramers.
J. Exp. Med. 191, 18951903 (2000).
100. Karadimitris, A. et al. Human CD1d-glycolipid
tetramers generated by in vitro oxidative refolding
chromatography. Proc. Natl Acad. Sci. USA 98,
32943298 (2001).
101. Matsuda, J. L. et al. Tracking the response of natural
killer T cells to a glycolipid antigen using CD1d
tetramers. J. Exp. Med. 192, 741754 (2000).
102. Gumperz, J. E., Miyake, S., Yamamura, T. & Brenner,
M. B. Functionally distinct subsets of CD1d-restricted
natural killer T cells revealed by CD1d tetramer
staining. J. Exp. Med. 195, 625636 (2002).
103. Lee, P. T., Benlagha, K., Teyton, L. & Bendelac, A.
Distinct functional lineages of human V24 natural
killer T cells. J. Exp. Med. 195, 637641 (2002).
104. Liu, T. Y. et al. Distinct subsets of human invariant
NKT cells differentially regulate T helper responses
via dendritic cells. Eur. J. Immunol. 38, 10121023
(2008).
105. Crowe, N. Y. et al. Differential antitumor immunity
mediated by NKT cell subsets in vivo. J. Exp. Med.
202, 12791288 (2005).
106. McNab, F. W. et al. Peripheral NK1.1 NKT cells are
mature and functionally distinct from their thymic
counterparts. J. Immunol. 179, 66306637
(2007).
107. Rachitskaya, A. V. et al. Cutting Edge: NKT cells
constitutively express IL-23 receptor and RORt and
rapidly produce IL-17 upon receptor ligation in an
IL-6-independent fashion. J. Immunol. 180,
51675171 (2008).
108. Michel, M. L. et al. Identification of an IL-17producing NK1.1neg iNKT cell population involved in
airway neutrophilia. J. Exp. Med. 204, 9951001
(2007).
109. Yoshiga, Y. et al. Invariant NKT cells produce IL-17
through IL-23-dependent and -independent pathways
with potential modulation of Th17 response in
collagen-induced arthritis. Int. J. Mol. Med. 22,
369374 (2008).
Acknowledgements
DATABASES
Entrez Gene: http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=gene
CD1d | CD40 | IFN | IL-4 | IL-12
FURTHER INFORMATION
Vincenzo Cerundolos homepage: http://www.imm.ox.ac.uk/
pages/research/human_immunology/enzo_cerundolo.htm
All liNkS ArE ACTivE iN ThE oNliNE pDf
www.nature.com/reviews/immunol
2009 Macmillan Publishers Limited. All rights reserved